Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 5 of 5 clinical reviews.
A detailed comparison of how the FDA and EMA regulate rosuvastatin (Crestor), including approval timelines, label differences, post-market safety monitoring, and clinical implications for prescribers.
Read clinical reviewA complete guide to rosuvastatin (Crestor) global regulatory status, FDA approval history, prescribing label highlights, and post-market safety data from JUPITER and FDA Sentinel surveillance.
Read clinical reviewA detailed timeline of every significant Crestor (rosuvastatin) FDA label change from 2020 through 2026, including new safety warnings, pediatric revisions, and post-market surveillance findings.
Read clinical reviewA detailed regulatory history of Crestor (rosuvastatin), covering FDA approval, Paragraph IV patent litigation, generic entry, safety label updates, and the JUPITER-driven indication expansion.
Read clinical reviewA complete regulatory overview of rosuvastatin (Crestor), covering FDA approval history, major label changes, post-market safety signals, generic field, and next-generation statin pipeline developments.
Read clinical review